← Back to patent-cliff list
KYN-5356
Tier C — Watch / tradeKYN-5356
Mitsubishi Tanabe Pharma Corp
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KAT-II
Indications (approved)：Ankylosing spondylitis, Schizophrenia, Cognitive impairment, Mild cognitive impairment
Regional status
US
Phase II
2025-08-27
EU
Phase I
2024-01-04
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of KYN-5356?
Approved indications include: Ankylosing spondylitis, Schizophrenia, Cognitive impairment, Mild cognitive impairment.
When does the KYN-5356 patent expire?
No public expiry year is available for KYN-5356 yet; this page updates once verified.
How do I get a quote for KYN-5356 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30